Life at Deloitte
Building long term partnerships that make a real and lasting difference
We are proud to focus on maximising impact for our charity partners through delivering strategic and value added support, enabling them to deal with key organisational challenges. We don’t just raise funds; over a three year period we provide our charity partners with time and expertise through volunteering and pro-bono support, creating sustainable solutions to community need.
Every office has a Corporate Responsibility Champion who organises local activities alongside our calendar of centrally managed events and challenges. Additionally, each year the firm allocates a matched funded amount for staff fundraising activities.
Our charity partners
The focus of our support until 31 May 2016 is on our three national charity partners, voted for by staff: Alzheimer’s Society, Mind and Prostate Cancer UK. Regional charities selected by regional offices are also supported through the partnership scheme.
Regional charities selected by regional offices are also supported through the partnership scheme.
Applications for our new society partnerships programme (2016-2019) have now closed. If you have submitted your entry to the programme and we have confirmed receipt, we will be in touch with you towards the end of March.
1 in 3 people over the age of 65 will die with dementia. The “Care for today, Cure for tomorrow” project will harness the skills of Deloitte people through the Dementia Support Service to make life better for the 1.5m people directly affected by dementia in the UK today, whilst funding the Deloitte Research Programme to help find a cure for tomorrow.
"Alzheimer’s Society is absolutely delighted to have been chosen as one of Deloitte’s charity partners for the next three years. The Care for today, Cure for tomorrow project will transform the lives of people with dementia across the UK by harnessing the skills of Deloitte people, funding our services and investing in pioneering research to help in the fight against the condition." - Jeremy Hughes, CEO, Alzheimer’s Society
1 in 4 people are experiencing a mental health problem in the UK right now. No one should face a mental health problem alone. Deloitte will help Mind reach over 4 million people by 2016, by expanding their helpline provision and using new technologies to reach people in need. Together we will empower 2000 employers, including through our clients and network to develop mentally healthy workplaces.
"We're thrilled to be working with Deloitte over the next three years. Mind is here to make sure anyone with a mental health problem has somewhere to turn for advice and support. None of our past or present partnerships delivers the scale of impact that working with Deloitte can bring to reaching out to thousands more people with mental health problems every year and promoting good mental health in workplaces across the UK. This is an encouraging sign that mental health is increasingly being recognised as a cause that is relevant to everyone, and that the stigma that surrounds it is finally starting to lift." - Paul Farmer, CEO, Mind
Prostate Cancer UK
Prostate Cancer kills one man every hour: one more family loses a father, brother, partner or son. Through a pioneering “Search and Rescue” programme Deloitte and Prostate Cancer UK will target the 1 in 8 men at high risk of this disease, in the hardest to reach communities across the UK. By empowering all Deloitte people to raise awareness we can further reach more than 300,000 people during a 3 year partnership.
"We are absolutely overjoyed to be Deloitte’s national charity partner for the next three years. Prostate cancer is a disease which kills one man every hour, and is set to become the most common cancer of all by 2030. There really is no better time to have Deloitte on our side to help us crack prostate cancer. Together we will transform the future for men and their families through a new Search and Rescue programme which will reach the men at highest risk of the disease with vital information and support. We look forward to our exciting three year journey." - Owen Sharp, CEO, Prostate Cancer UK